Veronica Mullally Muñoz is a Senior Partner in the Litigation Group at Pearl Cohen’s New York office. Veronica is a first chair trial lawyer. She has over 20 years of experience representing companies from Fortune 500 to start-ups and has broad experience in both bench and jury trials and in the appellate process. She regularly handles cases involving all types of intellectual property and commercial agreements. She has handled pantent infringement and theft of trade secret disputes involving a wide range of technologies including: pharmaceuticals, biologics, siRNA, gene sequencing, transgenic plants, cardiovascular stents, medical devices and mechanical, hightech, software and electrical products. Veronica also has extensive experience in HatchWaxman litigation including: achieving a favorable settlement of a 505(b)(2) case on the eve of trial; summary judgment of non-infringement in two successive ANDA cases and successfully defending a trial court's decision in the Court of Appeals for the Federal Circuit and on petition for certiorari to the United States Supreme Court. She has also successfully handled multiple copyright infringement cases.
Other representative matters include: obtaining a preliminary injunction on a breach of contract case involving an SAAS product; obtaining a preliminary injunction in a trade secret case involving siRNA; success in a priority of invention dispute at a bench trial in a Section 146 action involving a commercially valuable gene; a successful jury trial involving patented transgenic plant technology; forcing a withdrawal of suit and favorable settlements in infringement actions involving transgenic crops: four successful jury trials involving infringement of cardiovascular stent patents; arbitration involving licensing of a erythropoietintype biologic; successfully resolving an infringement case involving dental implant technology; and successful enforcement of a patent on photographic equipment.
Before attending law school, Veronica was a biochemist and worked in both academic research and in industry. She did post-graduate research on the gut hormone secretin and later worked on a leukemia research team at the John Radcliffe hospital in Oxford, UK. She went on to become a research scientist at Celltech Ltd., U.K., where she helped develop some of the first uses of monoclonal antibodies.